Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Treasury Shares: 2022-2025

Historic Treasury Shares for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $6.3 million.

  • Taysha Gene Therapies' Treasury Shares rose 37.85% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 37.85%. This contributed to the annual value of $4.5 million for FY2024, which is 1112.97% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Treasury Shares of $6.3 million as of Q3 2025, which was down 0.00% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Treasury Shares peaked at $6.3 million during Q2 2025, and registered a low of $375,044 during Q3 2023.
  • Its 3-year average for Treasury Shares is $3.6 million, with a median of $4.5 million in 2024.
  • In the last 5 years, Taysha Gene Therapies' Treasury Shares plummeted by 70.18% in 2023 and then surged by 1,112.97% in 2024.
  • Taysha Gene Therapies' Treasury Shares (Quarterly) stood at $1.3 million in 2022, then tumbled by 70.18% to $375,044 in 2023, then skyrocketed by 1,112.97% to $4.5 million in 2024, then soared by 37.85% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $6.3 million for Q2 2025, and $6.2 million during Q1 2025.